Can philanthropy rescue struggling small biotechs?
Can philanthropy rescue struggling small biotechs? Authors of a new essay believe so.
Morning. Today, we’re taking a look at the profound impact of funding cuts on cancer research under the Trump administration. Also, venture investors are pivoting away from gene therapies and leaning into faster-return areas like obesity and cancer.
Can philanthropy rescue struggling small biotechs?
Small biotech startups drive most drug innovation in the U.S., but they’re getting squeezed by the drug industry’s anti-competitive tactics and a patent system that rewards monopolies over breakthroughs, opine Boston University policy analyst Brian Stanley and Michael Nguyen-Maso, a fifth-year Ph.D. candidate in Harvard’s Health Policy and Economics Program.
